Cogent Biosciences (COGT) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" COGT shares.
View COGT analyst ratings or view top-rated stocks.

5 brokers have issued twelve-month price targets for Cogent Biosciences' shares. Their COGT share price forecasts range from $19.00 to $26.00. On average, they predict the company's share price to reach $21.60 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for COGT or view top-rated stocks among Wall Street analysts.

Cogent Biosciences' stock was trading at $11.56 on January 1st, 2023. Since then, COGT shares have decreased by 2.9% and is now trading at $11.23.
View the best growth stocks for 2023 here.

Cogent Biosciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,510,000 shares, a drop of 15.1% from the April 30th total of 5,310,000 shares. Based on an average daily trading volume, of 643,200 shares, the days-to-cover ratio is currently 7.0 days.
View Cogent Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our COGT earnings forecast.

Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Tuesday, March, 14th. The technology company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.06.

ETFs with the largest weight of Cogent Biosciences (NASDAQ:COGT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Vanguard U.S. Momentum Factor ETF (VFMO) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."

Cogent Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.11%), Commodore Capital LP (6.73%), State Street Corp (4.83%), Perceptive Advisors LLC (3.22%), Suvretta Capital Management LLC (2.56%) and Geode Capital Management LLC (1.86%). Insiders that own company stock include Fairmount Funds Management Llc and John L Green.
View institutional ownership trends.

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COGT stock can currently be purchased for approximately $11.23.

Cogent Biosciences (NASDAQ:COGT) has a market capitalization of $796.77 million and generates $7.87 million in revenue each year. The technology company earns $-140,240,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The official website for the company is www.cogint.com. The technology company can be reached via phone at (617) 945-5576 or via email at jkopin@cogint.com.